Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - il-prodotti terapewtiċi l-oħra kollha - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi winthrop industrie - riluzole - sklerożi laterali amyotrophic - drogi oħra tas-sistema nervuża - rilutek huwa indikat li jestendu l-ħajja jew il-ħin għall-mekkanika tal-ventilazzjoni għall-pazjenti b ' amyotrophic laterali sclerosis (als). provi kliniċi wrew li rilutek testendi s-sopravivenza għall-pazjenti bl-als. is-sopravivenza kienet definita bħala il-pazjenti li kienu ħajjin, ma intubated għal ventilazzjoni mekkanika u l-tracheotomy-free. ma hemm l-ebda evidenza li rilutek jeżerċita effett terapewtiku fuq funzjoni motorili, funzjoni tal-pulmun, faxxikulazzjonijiet, saħħa muskolari u sintomi motorili. rilutek ma ntweriex li hu effettiv fl-aħħar stadji ta ' als. is-sigurtà u l-effikaċja ta ' rilutek kienu studjati biss f'dawk li jbatu minn als. għalhekk, rilutek m'għandux jintuża f'pazjenti li għandhom xi forma oħra ta'vetturi bil-mutur-mard tan-newroni.

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - neoplażmi kolorettali - aġenti antineoplastiċi - kura tal-kanċer metastatiku tal-kolorektum (mcrc).

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - artrite, rewmatika - immunosoppressanti - kevzara flimkien ma ' methotrexate (mtx) huwa indikat għall-kura tal-moderat biex severament attiva rewmatojde artrite (ra) fil-pazjenti adulti li jkollhom irrispondiet jirriżultax, jew li huma intolerant għall-marda waħda jew aktar li jimmodifika anti-rheumatic id-drogi (dmards). kevzara jista 'jingħata bħala monoterapija f'każ ta' intolleranza għal mtx jew meta t-trattament b'mtx mhuwiex xieraq.

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - Ħnieżer - vaċċini - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 u 4. l-użu ta dengvaxia għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influwenza, bniedem - vaċċini - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - mard tal-Ħażna tal-glukoġen tat-tip ii - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulina glulisine - diabetes mellitus - drogi użati fid-dijabete - trattament ta 'adulti, adoloxxenti u tfal, ta' sitt snin jew aktar b'dijabete mellitus, fejn huwa meħtieġ it-trattament bl-insulina.

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi b.v. - vandetanib - neoplażmi tat-tirojde - aġenti antineoplastiċi u immunomodulanti - caprelsa huwa indikat għat-trattament ta 'kanċer tat-tirojde mediterrali (mtc) aggressiv u sintomatiku f'pazjenti b'mard ta' lokalizzazzjoni avvanzat jew metastatiku li ma jistax jitneħħa. caprelsa huwa indikat fl-adulti, it-tfal u l-adolexxenti li għandhom bejn 5-il sena u anzjani. għal pazjenti li għalihom rranġati mill-ġdid il-waqt il-trasfezzjoni(ret) mutazzjoni mhux magħrufa jew negattiv, jista'jkun aktar baxxi benefiċċju għandu jkun kkunsidrat qabel it-trattament individwali id-deċiżjoni tal -.